Lilly's oral weight-loss drug Foundayo approved; the only one that can be taken at any time without fasting.

Lilly’s oral GLP-1 weight-loss drug Foundayo has been approved for marketing by the U.S. Food and Drug Administration (FDA), marking the official entry of the global weight-loss drug market into a new era of oral medications.

On April 1, Lilly announced that Foundayo, taken once daily, is the only GLP-1 weight-loss tablet that can be taken at any time of day, with no dietary or drinking restrictions.

Immediate stock will be shipped via Lilly's direct sales platform LillyDirect and will subsequently be available in major US pharmacies and telemedicine platforms. Patients with insurance pay only $25 per month with Lilly coupons, while self-paying patients pay $149 to $349 per month depending on dosage.

According to Wall Street analysts compiled by Bloomberg, Foundayo sales are expected to reach $18 billion by 2030. On Wednesday, Lilly's U.S. stock price rose as much as 6% intraday, while competitor Novo Nordisk's ADR fell more than 2%.

(Lilly closed up nearly 4% Wednesday, while Novo Nordisk ADR slipped about 1%)

Rapid Approval, Only About Three Months Behind Novo Nordisk

Foundayo was approved in less than four months, thanks to the FDA’s accelerated review channel for innovative drugs deemed nationally significant.

After Lilly submitted the application this year, Foundayo’s launch was only about three months behind Novo Nordisk’s oral Wegovy, rapidly forming a competitive landscape between the two.

In 2018, Lilly acquired global rights to Foundayo’s active ingredient orforglipron from Japan’s Chugai Pharmaceutical for a $50 million upfront payment.

Currently, Lilly has stockpiled large inventories to ensure rapid market rollout and expects regulatory approval in more than 40 countries within the next year.

Since 2020, Lilly has invested more than $55 billion in manufacturing, including new construction and capacity expansion.

Slightly Less Effective, But Convenience and Accessibility Offer Unique Advantages

Efficacy is Lilly’s main challenge.

In their respective clinical trials, Wegovy's oral drug helped patients lose an average of about 13.6% of weight over 64 weeks, while Foundayo’s weight reduction ranges between 11% and 12.4% (with variation due to statistical methods).

By comparison, Lilly’s injectable Zepbound delivers over 20% weight reduction.

Nevertheless, physicians generally consider an approximately 11% weight reduction to be clinically meaningful.

Foundayo’s unique advantage lies in ease of use: patients can take it at any time of day, without fasting or water restrictions, whereas Wegovy's oral drug must be taken in the morning on an empty stomach, with a small amount of water, and a 30-minute wait before eating.

Lilly CEO Dave Ricks told the media that injections did not become the main barrier to treatment as initially expected, but he views Foundayo as an important option for patients who prefer oral medication or seek lower prices.

Global Expansion Potential May Be Foundayo’s Biggest Highlight

Foundayo and Zepbound are fundamentally different products.

Foundayo is a small molecule compound, while Zepbound and Wegovy injectables are peptide drugs, the latter requiring more complex manufacturing and stringent cold-chain logistics. This characteristic gives Foundayo a unique advantage for rapid global expansion.

Ricks said:

This enables scalable production, allowing us to launch worldwide simultaneously as soon as regulatory approval is received. We basically already have the capacity needed to supply oral GLP-1 inhibitors globally.

Currently, oral Wegovy is only sold in the U.S. and has not been rolled out to other markets.

Ricks added that as a small-molecule drug, Foundayo will naturally avoid competitive pressure from generic oral Wegovy in markets such as India, since peptide drugs are more difficult to replicate.

Pricing Is Key Variable, Medicare Expansion Unlocks New Demand

For pricing, both drugs’ lowest initial dosage costs the same—$149 per month for self-paying patients, originating from a prior agreement Lilly and Novo Nordisk reached with the Trump administration.

Starting this summer, elderly patients covered by Medicare will only pay $50 per month for Foundayo and other GLP-1 weight-loss drugs, as part of the above agreement. Ricks expects this program to generate "quite strong" demand, and that expectation is included in Lilly’s annual financial guidance.

Nidhi Kansal, an obesity specialist at Northwestern Medicine, noted that price is currently the main factor in clinical drug choice. She said:

Unfortunately, price drives the decision-making for physicians and patients, because these drugs are all excellent. We have many options now, but ultimately, it’s an economic decision.

BMO Capital Markets analyst Evan David Seigerman believes that a lower price threshold combined with oral drug affinity will attract previously hesitant potential patients, further expanding the weight-loss drug market.

Foundayo Approval Is A Key Signal For Lilly Stock Stabilization

Analysts generally believe that whether Foundayo can successfully scale up sales is crucial for Lilly’s stock trajectory.

Lilly’s stock has fallen about 14% from its peak this year; its market capitalization briefly topped $1 trillion, making it the first U.S. healthcare company to cross that threshold.

Cantor Fitzgerald analyst Carter Gould said that sales data lags actual demand, so the market will closely monitor prescription volume to assess Foundayo's market penetration. He said:

If prescription volume trends improve and maintain momentum, I expect investors will tolerate performance fluctuations for a quarter or two.

Meanwhile, key clinical data from Lilly's more potent injectable weight-loss drug retatrutide is another major catalyst. Lilly has released some late-stage data, but core trials focused specifically on weight-loss effects are yet to be published.

Analysts believe that if retatrutide’s results meet expectations, Lilly will achieve a complete obesity drug product portfolio spanning oral and injectable medications with varying efficacy levels.

FactSet data shows analyst sales projections for 2030: Foundayo ~$14.8 billion, Zepbound ~$24.7 billion, and Mounjaro (approved for diabetes in the U.S., for diabetes and obesity elsewhere) ~$44.9 billion.

Risk Warning and DisclaimerThe market has risks. Investment should be done with caution. This article does not constitute personal investment advice, nor does it consider individual users’ specific investment goals, financial situation or needs. Users should consider whether any opinions, viewpoints or conclusions in this article are suitable for their circumstances. You are responsible for any investment you make based on this information.